# Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients

> **NCT05447013** · PHASE1,PHASE2 · UNKNOWN · sponsor: **George Papanicolaou Hospital** · enrollment: 182 (estimated)

## Conditions studied

- Severe COVID-19

## Interventions

- **BIOLOGICAL:** Coronavirus-2-specific T cells
- **OTHER:** standard of care (SOC)

## Key facts

- **NCT ID:** NCT05447013
- **Lead sponsor:** George Papanicolaou Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-02
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 182 (ESTIMATED)
- **Last updated:** 2022-11-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05447013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05447013, "Generation of SARS-CoV-2-specific T Lymphocytes From Recovered Donors and Administration to High-risk COVID-19 Patients". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT05447013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*